Impact News +++ Health Catalyst jumps on announcement to sell Vitalware to Med‑Metrix for $147M (SeekingAlpha) +++ HEALTH CATALYST Aktie +40,18%

QUOIN Aktie

>QUOIN Aktienkurs

3.66 EUR (TradegateBSX)

Ask: 3.74 EUR / 2700 Stück

Bid: 3.58 EUR / 2800 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

QUOIN Aktie über LYNX handeln

Intraday

1 Jahr

>QUOIN Performance

1 Woche: -10,1%

1 Monat: -23,5%

3 Monate: -47,9%

6 Monate: -76,2%

1 Jahr: -46,3%

laufendes Jahr: -67,7%

>QUOIN Aktie

Name:

QUOIN PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US74907L4095 / A41BEM

Symbol/ Ticker:

2EB0 (Frankfurt) / QNRX (NASDAQ)

Kürzel:

FRA:2EB0, ETR:2EB0, 2EB0:GR, NASDAQ:QNRX

Index:

Webseite:

https://quoinpharma.com/

Profil:

Quoin Pharmaceuticals Ltd. - American Depositary Receipt represents shares in a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. The company focuses on unme..
>Volltext..

Marktkapitalisierung:

8.05 Mio. EUR

Unternehmenswert:

-4.03 Mio. EUR

Umsatz:

EBITDA:

-15.03 Mio. EUR

Nettogewinn:

-14.71 Mio. EUR

Gewinn je Aktie:

-203.58 EUR

Schulden:

Liquide Mittel:

2.69 Mio. EUR

Operativer Cashflow:

Bargeldquote:

2.63

Umsatzwachstum:

Gewinnwachstum:

-63.73%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

QUOIN

Letzte Datenerhebung:

04.06.26

>QUOIN Kennzahlen

Aktien/ Unternehmen:

Aktien: 1.96 Mio. St.

Frei handelbar: -

Leerverk. Aktien: -

Rückkaufquote: -200.91%

Mitarbeiter: 4

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 552.41%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.02

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -119.39%

Eigenkaprendite: -232.69%

>QUOIN Peer Group

Gesundheit, Hauterkrankungen & -behandlung/ Dermatologie

>QUOIN Chart & Kurs - NASDAQ

>QUOIN News

04.06.26 - 14:33	Quoin Pharmaceuticals Announces Japan′s MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval-...

02.06.26 - 15:31	Quoin Pharmaceuticals: Aktie legt nach IND-Antrag für seltene Krankheit zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.06.26 - 14:33	Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome (GlobeNewswire EN)
	-First ever IND submission for this disease, which has no current treatment or cure-...

19.05.26 - 12:33	Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline \| DelveInsight (PR Newswire)
	LAS VEGAS, May 19, 2026 /PRNewswire/ -- The Netherton syndrome market size is expected to grow during the forecast period (2026–2036), primarily driven by the launch of upcoming therapies such as QRX003 (Quoin Pharmaceuticals), BCX17725 (BioCryst Pharmaceuticals), ATR-12 (Azitra), and......

07.05.26 - 14:33	Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire EN)
	– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome...

30.04.26 - 14:33

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 (GlobeNewswire EN)

ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 7, 2026....

28.04.26 - 18:06	CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs (GlobeNewswire EN)
	Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications....

26.03.26 - 13:33	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire EN)
	– Closes Private Placement Financing of Up to $104.5 Million...

25.03.26 - 13:33	Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S....

24.03.26 - 13:31	FM BANK and Quoin Financial Bank Select Jack Henry to Elevate Service (PR Newswire)
	Midwestern banks to gain competitive edge with modern banking experiences MONETT, Mo., March 24, 2026 /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) announced today that Independent Bancshares Inc., the holding company of FM BANK and Quoin Financial Bank, has selected Jack Henry to strengthen......

19.03.26 - 13:33

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 (GlobeNewswire EN)

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026....

11.03.26 - 13:33	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire EN)
	— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —...

27.01.26 - 14:33	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status...

20.01.26 - 14:33	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome (GlobeNewswire EN)
	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome...

11.11.25 - 15:30	Quoin Pharmaceuticals: Aktie springt nach Meilenstein bei Rapamycin-Formulierung um 66 % (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 14:33	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies (GlobeNewswire EN)
	Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively...

06.11.25 - 14:33	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results (GlobeNewswire EN)
	– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D...

04.11.25 - 21:30	Prysmian Hosts Ribbon Cutting Ceremony to Unveil $63.8M Du Quoin Facility Expansion (Accesswire)
	DU QUOIN, IL / ACCESS Newswire / November 4, 2025 / Prysmian, a world leader in the energy transition and digital transformation, recently held a ribbon cutting ceremony to officially unveil the co......

30.10.25 - 13:33

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (GlobeNewswire EN)

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025....

28.10.25 - 14:18	Quoin Pharmaceuticals: Aktie steigt nach positiven Daten aus pädiatrischer Studie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn in Salzburg nicht endlich ein wirklich geistiger Prozess eingeleitet wird, ist das Festival am Ende. - Dr. Gérard Mortier

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram